Back to Journals » Drug Design, Development and Therapy » Volume 10

Calycosin inhibits migration and invasion through modulation of transforming growth factor beta-mediated mesenchymal properties in U87 and U251 cells

Authors Nie X, Jia O, Xing Y, Li D, Liu R, Xu R

Received 14 June 2015

Accepted for publication 15 December 2015

Published 22 February 2016 Volume 2016:10 Pages 767—779

DOI https://doi.org/10.2147/DDDT.S90457

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Wei Duan


Xiao-hu Nie,1,* Jia Ou-yang,2,* Ying Xing,3 Dan-yan Li,4 Ru-en Liu,5 Ru-xiang Xu6

1Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang, 2Nanchang University Medical College, Nanchang, Jiangxi, 3Department of Gastroenterology, The 98th Hospital of Nanjing Military Command, Huzhou, Zhejiang, 4Spleen & Stomach Institute, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, 5Department of Neurosurgery, China–Japan Friendship Hospital, Beijing, 6Bayi Brain Hospital, The Military General Hospital of Beijing PLA, Beijing, People’s Republic of China

*These authors contributed equally to this work

Abstract: In this study, we investigated the potential anticancer effects of calycosin against human glioblastoma cells, including the impacts on cell proliferation, apoptosis, and cell cycle distribution. We further studied its inhibitory activity on migration and invasion in U87 and U251 cells. Furthermore, transforming growth factor beta-mediated reductions of mesenchymal-associated genes/activators, matrix metalloproteinases-2, and -9 were detected in this process. Administration of calycosin in a glioblastoma xenograft model showed that calycosin could not only reduce tumor volume but also suppress transforming growth factor beta as well as its downstream molecules. These results revealed calycosin as a potential antitumor agent in human glioblastoma.

Keywords: calycosin, migration, invasion, epithelial–mesenchymal transition (EMT), matrix metalloproteinases (MMPs), glioblastoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]